Controlled-Release Psilocybin Dosing Below Hallucinogenic Thresholds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceuticals targeting serotonin pathways for treating mood disorders have long onset times, severe side-effects, and poor efficacy, posing risks to users, while psilocybin-based treatments are limited by adverse effects such as hallucinations and nausea.
Innovation Solution
Development of low-dose pharmaceutical compositions containing 5HT receptor agonists like psilocin or psilocybin, administered in controlled release formulations to provide therapeutic effects without adverse side effects, with plasma concentrations below 6 ng/ml to avoid hallucinogenic experiences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dose psilocybin is administered to treat mood disorders, then therapeutic effect is improved, but adverse side effects (hallucinations, nausea, panic attacks) increase
Solution Approach 1:
The patent applies parameter changes by precisely controlling the dosage of psilocybin to fall within a specific therapeutic window (0.1-10 mg for adults, with plasma concentrations maintained below 6 ng/ml). This dosage optimization resolves the contradiction by identifying the precise parameter range where therapeutic benefits are maximized while adverse effects are minimized or eliminated.
Solution Approach 2:
The patent employs dynamic dosing strategies including controlled release formulations that maintain plasma concentrations within the therapeutic window over time. The dosing regimen is dynamically adjusted based on individual patient response, tolerance, and metabolic factors, allowing the therapy to adapt and maintain effectiveness while avoiding adverse effects.
2Reliability
If conventional serotonin-targeting pharmaceuticals are used, then mood disorders are treated, but onset time is prolonged and side effects are severe
Solution Approach 1:
The patent extracts and isolates psilocybin as the active therapeutic agent, separating it from the complex mechanisms and multiple compounds found in conventional antidepressants. This extraction allows for more direct and rapid action on serotonin receptors, reducing onset time while maintaining therapeutic efficacy.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of serotonin modulation by using psilocybin's unique metabolic pathway (conversion to psilocin) and its specific receptor binding characteristics. This results in faster onset of action compared to conventional SSRIs or MAOIs, while the controlled dosage parameters prevent severe side effects.
3Adaptability or versatility
If psilocybin is administered to treat anxiety and mood disorders, then therapeutic potential is improved, but adverse effects (hallucinations, psychosis, nausea) occur
Solution Approach 1:
The patent applies parameter changes by establishing a precise therapeutic window for psilocybin dosage and plasma concentration. By maintaining concentrations below 6 ng/ml and using dosages within the 0.1-10 mg range, the patent maximizes adaptability to treat various mood and anxiety disorders while minimizing the risk of hallucinations, psychosis, and other adverse effects.
Solution Approach 2:
The patent uses psilocin (the active metabolite of psilocybin) as an intermediary that mediates the therapeutic effects. Psilocybin itself is relatively inactive and serves as a prodrug that converts to psilocin in the body, allowing for controlled delivery of the active compound at therapeutic levels without the adverse effects associated with higher doses.
4Reliability
If prescription drugs targeting serotonin are used, then mood disorders are treated, but severe side effects (suicidal thoughts, sexual dysfunction, fatigue, elevated blood pressure) occur
Solution Approach 1:
The patent changes the dosage parameters from the high doses required by conventional antidepressants to low doses of psilocybin (0.1-10 mg). This parameter change achieves therapeutic effects while avoiding the severe side effects associated with chronic use of SSRIs, SNRIs, and other conventional serotonin-targeting medications.
Solution Approach 2:
The patent employs periodic administration of psilocybin rather than continuous daily dosing. Treatment protocols typically involve 1-3 sessions spaced weeks apart, allowing the brain to integrate therapeutic effects without the cumulative side effects of continuous pharmacological intervention. This periodic action maintains therapeutic benefits while minimizing adverse effects.
Data Source
AI summary
Disclosed herein are methods for managing disorders or conditions, or treating symptoms of disorders or conditions, comprising administering 5HT receptor agonists. The disorders may involve cognitive function and the methods of improving may comprise administering low doses of 5HT receptor agonists to subjects in need thereof. Improvement of the symptoms of a disorder involving cognitive function can be achieved where the disorders comprise mood, cognitive, anxiety, and depression disorders. Also disclosed herein are pharmaceutical compositions, formulations, and dosage forms of 5HT receptor agonists.